Prevalence of cannabis use disorder among individuals using medical cannabis at admission to inpatient treatment for substance use disorders

被引:5
|
作者
Gendy, Marie N. S. [1 ,2 ,3 ,4 ]
Taisir, Radia [4 ]
Sousa, Sarah [4 ]
Costello, Jean [4 ]
Rush, Brian [4 ,5 ]
Busse, Jason W. [2 ,6 ]
Mackillop, James [1 ,2 ,3 ,4 ,7 ,8 ,9 ,10 ]
机构
[1] McMaster Univ, Peter Boris Ctr Addict Res, Hamilton, ON, Canada
[2] St Josephs Healthcare Hamilton, Hamilton, ON, Canada
[3] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada
[4] Homewood Res Inst, Guelph, ON, Canada
[5] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[6] McMaster Univ, Dept Anesthesia, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[7] McMaster Univ, Michael G DeGroote Ctr Med Cannabis Res, Hamilton, ON, Canada
[8] McMaster Univ, Dept Psychol Neurosci & Behav, Hamilton, ON, Canada
[9] McMaster Univ, Peter Boris Ctr Addict Res, Dept Psychiat & Behav Neurosci, Hamilton, ON L8P 3P2, Canada
[10] St Josephs Healthcare Hamilton, Hamilton, ON L8P 3P2, Canada
关键词
Cannabis; Cannabis use disorder; Medical cannabis; Recreational cannabis; Substance use disorders; Addiction treatment; MENTAL-HEALTH; DEPRESSION; ANXIETY; ASSOCIATION; MARIJUANA;
D O I
10.1016/j.addbeh.2023.107667
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: Cannabis is used for medical and recreational purposes and may result in cannabis use disorder (CUD). This study explored the prevalence of cannabis use disorder and other psychiatric comorbidities among inpatients undergoing treatment for substance use disorder who reported medical cannabis use at admission.Methods: We assessed CUD and other substance use disorders based on DSM-5 symptoms, anxiety with the Generalized Anxiety Disorder scale (GAD-7), depression with the Patient Health Questionnaire (PHQ-9), and post-traumatic stress disorder with the PTSD Checklist for DSM-5 (PCL-5). We compared the prevalence of CUD and other psychiatric comorbidities between inpatients who endorsed the use of cannabis for medical purposes only vs those endorsing use for medical and recreational purposes.Results: Among 125 inpatients, 42% reported medical use only, and 58% reported medical and recreational use (dual motives). For CUD, 28% of Medical-Only and 51% of Dual-Use motives patients met the diagnostic criteria for CUD (p = 0.016). High psychiatric comorbidities were present: 79% and 81% screened positive for an anxiety disorder, 60% and 61% screened positive for depression, and 66% and 57% screened positive for PTSD for the Medical-Only and Dual-Use inpatients, respectively.Conclusions: Many treatment-seeking individuals with substance use disorder who report medical cannabis use meet criteria for CUD, particularly those reporting concurrent recreational use.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Cannabis use and cannabis use disorders among individuals with mental illness
    Lev-Ran, Shaul
    Le Foll, Bernard
    McKenzie, Kwame
    George, Tony P.
    Rehm, Juergen
    COMPREHENSIVE PSYCHIATRY, 2013, 54 (06) : 589 - 598
  • [2] PREVALENCE AND CORRELATES OF CANNABIS USE DISORDER AMONG AUSTRALIAN MEDICAL CANNABIS USERS
    Mills, Llewellyn
    Lintzeris, Nicholas
    O'Malley, Michael
    Arnold, Jonathon C.
    Mcgregor, Iain S.
    DRUG AND ALCOHOL REVIEW, 2021, 40 : S109 - S109
  • [3] Cannabis use disorder and substance use treatment among US adults
    Choi, Namkee G.
    Moore, John
    Choi, Bryan Y.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 167
  • [4] Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
    Mills, Llewellyn
    Lintzeris, Nicholas
    O'Malley, Michael
    Arnold, Jonathon C.
    McGregor, Iain S.
    DRUG AND ALCOHOL REVIEW, 2022, 41 (05) : 1095 - 1108
  • [5] Characteristics of substance use disorder treatment patients using medical cannabis for pain
    Ashrafioun, Lisham
    Bohnert, Kipling M.
    Jannausch, Mary
    Ilgen, Mark A.
    ADDICTIVE BEHAVIORS, 2015, 42 : 185 - 188
  • [6] Has the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders?
    Leung J.
    Chiu C.Y.V.
    Stjepanović D.
    Hall W.
    Current Addiction Reports, 2018, 5 (4) : 403 - 417
  • [7] Cannabis legislation and substance use disorder treatment
    Schwartz, Maria K. D.
    Connery, Hilary
    AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (02): : 127 - 129
  • [8] Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder
    Streck, Joanna M.
    Regan, Susan
    Bearnot, Benjamin
    Gupta, Priya S.
    Kalkhoran, Sara
    Kalagher, Kelly M.
    Wakeman, Sarah
    Rigotti, Nancy A.
    SUBSTANCE USE & MISUSE, 2022, 57 (07) : 1104 - 1110
  • [9] Nicotine and cannabis vaping among adolescents in treatment for substance use disorders
    Young-Wolff, Kelly C.
    Adams, Sara R.
    Sterling, Stacy A.
    Tan, Andy S. L.
    Salloum, Ramzi G.
    Torre, Kira
    Carter-Harris, Lisa
    Prochaska, Judith J.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 125
  • [10] Cannabis use and cannabis use disorders and their treatment in the Europe
    Hall, Wayne
    Manthey, Jakob
    Stjepanovic, Daniel
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2025, 275 (02) : 307 - 313